35 research outputs found
Capecitabine and Temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis
Background
Retrospective studies and single center experiences suggest a role of capecitabine combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs).
Methods
We performed a systematic review to assess the efficacy and safety of CAPTEM in patients affected with NENs, with the aim to better clarify the role of this regimen in the therapeutic algorithm of NENs.
Results
A total of 42 articles and 1818 patients were included in our review. The overall disease control rate was 77% (range 43.5%-100%). The median progression free survival ranged from 4 to 38.5 months, while the median overall survival ranged from 8 to 103 months. Safety analysis showed an occurrence of G3-G4 toxicities in 16.4% of the entire population. The most common toxicities were hematological (27.2%), gastrointestinal (8.3%,) and cutaneous (3.2%).
Conclusion
This systematic review demonstrated that CAPTEM was an effective and relatively safe treatment for patients with advanced well-moderate differentiated NENs of gastroenteropancreatic, lung and unknown origin
Glutathione infusion before primary percutaneous coronary intervention: A randomised controlled pilot study
Objective: In the setting of reperfused ST-elevation myocardial infarction (STEMI), increased production of reactive oxygen species (ROS) contributes to reperfusion injury. Among ROS, hydrogen peroxide (H2O2) showed toxic effects on human cardiomyocytes and may induce microcirculatory impairment. Glutathione (GSH) is a water-soluble tripeptide with a potent oxidant scavenging activity. We hypothesised that the infusion of GSH before acute reoxygenation might counteract the deleterious effects of increased H2O2 generation on myocardium. Methods: Fifty consecutive patients with STEMI, scheduled to undergo primary angioplasty, were randomly assigned, before intervention, to receive an infusion of GSH (2500 mg/25 mL over 10 min), followed by drug administration at the same doses at 24, 48 and 72 hours elapsing time or placebo. Peripheral blood samples were obtained before and at the end of the procedure, as well as after 5 days. H2O2 production, 8-iso-prostaglandin F2α (PGF2α) formation, H2O2 breakdown activity (HBA) and nitric oxide (NO) bioavailability were determined. Serum cardiactroponin T (cTpT) was measured at admission and up to 5 days. Results: Following acute reperfusion, a significant reduction of H2O2 production (p=0.0015) and 8-iso-PGF2α levels (p=0.0003), as well as a significant increase in HBA (p<0.0001)and NO bioavailability (p=0.035), was found in the GSH group as compared with placebo. In treated patients, attenuated production of H2O2 persisted up to 5 days from the index procedure (p=0.009) and these changes was linked to those of the cTpT levels (r=0.41, p=0.023). Conclusion: The prophylactic and prolonged infusion of GSH seems to determine a rapid onset and persistent blunting of H2O2 generation improving myocardial cell survival. Nevertheless, a larger trial, adequately powered for evaluation of clinical endpoints, is ongoing to confirm the current finding
Electrochemotherapy for solid tumors: literature review and presentation of a novel endoscopic approach
Background: Electrochemotherapy (ECT) is a minimally invasive and safe treatment gaining positive and long-lasting antitumoral results that are receiving the attention of the scientific community. It is a local treatment that combines the use of electroporation and the administration of cytotoxic drugs to induce cell death in the target tissue. ECT is largely used for the treatment of cutaneous and subcutaneous lesions, and good results have been reported for the treatment of deep visceral tumors. The latest literature review is provided. Moreover, in line with its development for the treatment of visceral tumors in this article, we describe a novel approach of ECT: endoscopic treatment of colorectal cancer. Endoscopic ECT application was combined with systemic chemotherapy in the treatment of obstructing rectal cancer without prospective surgery. A good response after ECT was described: concentric involvement of the rectum was reduced, and no stenosing lesions were detected.
Conclusions: Clinical studies have demonstrated that ECT is a very effective treatment for tumors of different histologic types and localizations. Endoscopic treatment for gastrointestinal cancer is an innovative application of ECT. The combination of systemic treatment and ECT was safe and highly effective in the treatment of colorectal cancer, especially when obstructive, giving the patient a significant gain in quality of life
Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients. The new drug-pin® system comprehensive approach
Drug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN® (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual genetic polymorphisms. Inclusion criteria were: (i) stage II-IV CRC; (ii) ECOG PS (Performance status sec. Eastern coperative oncology group) ≤2; (iii) ≥5 concomitant drugs; and (iv) adequate renal, hepatic, and bone marrow function. The Drug-PIN® system analyzes interactions between active and/or pro-drug forms by integrating biochemical, demographic, and genomic data from 110 SNPs. We selected DDI, DrugPin1, and DrugPin2 scores, resulting from concomitant medication interactions, concomitant medications, and SNP profiles, and DrugPin1 added to chemotherapy drugs, respectively. Thirty-four patients, taking a median of seven concomitant medications, were included. The median DrugPin1 and DrugPin2 scores were 42.6 and 77.7, respectively. In 13 patients, the DrugPin2 score was two-fold higher than the DrugPin1 score, with 7 (54%) of these patients experiencing severe toxicity that required hospitalization. On chi-squared testing for any toxic-ity, a doubled DrugPin2 score (p = 0.001) was significantly related to G3–G4 toxicity. Drug-PIN® software may prevent severe adverse events, decrease hospitalizations, and improve survival in cancer patients
The Physical activity behaviour of vulnerable diabetic migrants: the role of juridical status
n/
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference
Purpose: BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients according to BRAF mutations, with the aim to identify any predictive factors of response to targeted-based therapy. Methods: A retrospective study of RCC patients, with BRAF known mutation status, treated with chemotherapy (CT) from October 2008 to June 2019 in 5 Italian centers, was conducted. Results: We identified 207 advanced RCC patients: 20.3% BRAF mutant and 79.7% BRAF wild type (wt). BRAF-mutant cancers were more likely to be pT4 (50.0% v 25.7%, p = 0.016), undifferentiated (71.4% v 44.0%, p = 0.004), KRAS wt (90.5% v 38.2%, p < 0.001), and MSI-H (41.7% v 16.2%, p = 0.019) tumors, with synchronous (52.4% v 31.5%, p = 0.018) and peritoneal metastases (38.1% v 22.4%, p = 0.003). Median overall survival (OS) was 16 v 27 months in BRAF mutant and BRAF wt (P = 0.020). In first-line setting, BRAF-mutant showed a 2ys OS of 80% in clinical trials, 32% in anti-VEGF, 14% in epidermial growth factor receptor (EGFR), and 0% in chemotherapy alone regimens (P = 0.009). BRAF-mutant patients demonstrated worse survival, regardless of targeted therapy administered. However, survival difference was statistically significant in the anti-EGFR-treated subgroup (16 v 28 months, P = 0.005 in BRAF mutant v BRAF wt, respectively). Conclusions: Our study demonstrated that BRAF status makes the difference in treatment’s outcome. Therefore, the anti-EGFR should not be excluded in all advanced RCC but considered on a case-by-case basis
HPV in gravidanza: stato dell’arte e nostra valutazione clinica dei più appropriati metodi diagnostici e terapeutici
L’HPV (Papillomavirus umano) è l’agente eziologico dei condilomi genitali, capace di penetrare attraverso minime abrasioni della cute e delle mucose durante i rapporti sessuali e trasmissibile anche per fomiti.
Attualmente è ritenuto il principale responsabile della genesi del cervicocarcinoma e dei suoi precursori, in particolare HPV-16 e 18. L’infezione da HPV compare in giovani donne sessualmente attive e sembra che la gravidanza favorisca lo sviluppo di tale infezione per il diverso bilancio ormonale e immunitario. La diagnosi è prevalentemente clinica e citologica, riservando l’utilizzo di biotecnologie molecolari, quali il Southern Blot
per la ricerca del genoma virale, alle lesioni sospette o asintomatiche. Tuttavia, l’esame citooncologico rimane il gold standard per la scoperta e la caratterizzazione delle lesioni da HPV. La terapia prevede il trattamento dei condilomi con la CO2 vaporizzazione laser, che consente un approccio terapeutico sicuro ed efficace sulle lesioni
da HPV in gravidanza
Carcinoma mammario in gravidanza
Il carcinoma della mammella in gravidanza è quel tumore che viene diagnosticato durante la gravidanza o l’allattamento e fino ad un anno dopo il parto.
I dati riportati in letteratura sono estremamente variabili,ma una stima attendibile, verificata anche nella nostra pratica clinica quotidiana, pone l’associazione intorno a valori del 2.5% di tutti i carcinomi mammari.
Inoltre sottolineiamo come il tumore della mammella sia soprattutto una patologia età -correlata, un dato importante proprio perché le donne tendono a concepire in età più avanzata rispetto al passato. È stato calcolato un ritardo diagnostico compreso tra 5-10 mesi, dovuto sia ad una minore attendibilità dell’esame obiettivo, per la congestione della ghiandola mammaria, sia alla tendenza della donna a rimuovere la possibilità della malattia, sia alla paura che accertamenti diagnostici più approfonditi
possano danneggiare il feto. Bisogna, però, precisare che l’iter diagnostico rimane sostanzialmente invariato facendo uso, ovviamente, di tutti gli accorgimenti necessari a minimizzare i rischi per il feto. Il nostro intento è quello di porre l’attenzione sulla necessità che lo screening per il cancro al seno venga anticipato almeno a 34-35 anni di età e, in particolare, per quelle donne che stanno programmando una gravidanza
Undetected acute aortic dissection in a patient referred for primary coronary angioplasty: A successful treatment of perioperative bleeding after abciximab administration
The authors describe a case of an acute aortic dissection in a Japanese woman with long-lasting hypertension, who was referred to our cath lab for primary percutaneous coronary intervention because of an ECG feature of acute inferior myocardial infarction and systemic hypotension. A successful treatment of perioperative bleeding followed a missed diagnosis in the early stages and abciximab administration